Clinical trials have demonstrated the safety of NeuroStar TMS Therapy® in treating patients who have had an inadequate response to prior antidepressant medications.
Treatment with NeuroStar TMS Therapy caused very few side effects and was generally well tolerated by patients. The most common side effect reported during clinical trials was scalp discomfort—generally mild to moderate and occurring less frequently after the first week of treatment.
Fewer than 5% of patients discontinued treatment with NeuroStar TMS Therapy due to adverse events.
Over 10,000 active treatments were performed across all NeuroStar® clinical trials demonstrating its safety
NeuroStar TMS Therapy is contraindicated in patients with implanted metallic devices or non-removable metallic objects in or around the head. Please refer to www.NeuroStar.com for complete product safety information.
The risk of emergent suicidal ideation is a concern with any antidepressant treatment. It can be seen that virtually all instances occurred only in the Sham treatment condition, versus the NeuroStar TMS Therapy. This indicates that TMS is not associated with provoking emergent suicidal ideation during acute treatment in the indicated patient population.